Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (19687)	4/8/2006 5:24:25 PM
From: ewolf	Read Replies (1) \| Respond to of 52153

I wonder if anyone would like to comment on what differentiates good management from bad management. Is it simply defined broadly by success or failure? I think Incy's management is good. They are decisive, realistic, honest and they've managed to diversify the company with reasonably good alternatives in spite of their hiv treatment blow up. But they did fail and their stock imploded. Epix was blindsided by changing standards at the FDA. Was Michael Webb to blame? It often seems like a fine line that I don't understand. Cbst came dangerously close to running out of money. Xoma survives for longer than I can remember. Dsco gets a drug approved but can't manufacture it. Where did Ligand management miss the boat? Were their assets overrated? Elan followers berate Kelly Martin but wasn't he a victim of circumstance?/ tysabri perhaps caused a tragic side effect definitely at the wrong time. I do get the reaction to Osip's acquisition. That seems clear cut. But when Medx does its secondary or Mygn tries to advance its less than stunning alzheimer's drug, it isn't clear whether managements are pursuing opportunity or harming shareholder value.